The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel

Abstract excerpt

BACKGROUND: Different platelet function tests can be used to evaluate the degree of achieved platelet inhibition in patients treated with clopidogrel. The presence of CYP 2C19*2 polymorphism can reduce the formation of the active metabolite of clopidogrel, resulting in less platelet inhibition. PATIENTS AND METHODS: Patients with symptomatic coronary artery disease, all on chronic single aspirin treatment were...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antiplatelet Therapy and Cardiovascular Diseases
• Share to Heparin-Induced Thrombocytopenia and Thrombosis
• Share to Platelet Disorders and Treatments